Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
复制标题
DOI：
10.1093/infdis/jiab563
复制
发表时间：
2022-03-15
期刊：
影响因子：
--
通讯作者：
Harvala H
中科院分区：
文献类型：
--
作者：
Nguyen D;Xiao J;Simmonds P;Lamikanra A;Odon V;Ratcliff J;Townsend A;Roberts DJ;Harvala H
我们比较了在严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）新菌株出现之前和之后收集的恢复期样本中针对野生型病毒和α（B.1.1.7）和β（B.1.351）变体的中和抗体滴度。在2020年出现变异体之前采集的血浆样本显示针对α变异体的滴度降低，两组样本均显示针对β变异体的滴度显著降低。与假型和血凝试验获得的微量中和滴度的比较表明，它们的滴度和菌株变异的影响之间有很好的相关性，支持使用这些更简单的检测方法来评估恢复期血浆对目前流行和新出现的SARS-CoV-2菌株的效力。与野生型病毒相比，在第一波大流行期间收集的恢复期血浆显示出对α变体的中和能力显著降低，这突出了在临床使用前评估其对当前流行毒株的效力的重要性。
We compared neutralizing antibody titers of convalescent samples collected before and after the emergence of novel strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), against the wild-type virus and Alpha (B.1.1.7) and Beta (B.1.351) variants. Plasma samples collected in 2020 before emergence of variants showed reduced titers against the Alpha variants, and both sets of samples demonstrated significantly reduced titers against Beta. Comparison of microneutralization titers with those obtained with pseudotype and hemagglutination tests showed a good correlation between their titers and effects of strain variation, supporting the use of these simpler assays for assessing the potency of convalescent plasma against currently circulating and emerging strains of SARS-CoV-2. Convalescent plasma collected during the first pandemic wave showed significantly reduced neutralization capacity against the Alpha variant when compared with wild-type virus, highlighting the importance of assessing its potency against currently circulating strains before clinical use.
登录
查看更多内容
影响因子：
16.6
作者：
Greaney AJ;Starr TN;Barnes CO;Weisblum Y;Schmidt F;Caskey M;Gaebler C;Cho A;Agudelo M;Finkin S;Wang Z;Poston D;Muecksch F;Hatziioannou T;Bieniasz PD;Robbiani DF;Nussenzweig MC;Bjorkman PJ;Bloom JD
通讯作者：
Bloom JD
DOI：
10.1111/tme.12746
发表时间：
2021-06
期刊：
Transfusion medicine (Oxford, England)
影响因子：
--
作者：
Harvala H;Robb ML;Watkins N;Ijaz S;Dicks S;Patel M;Supasa P;Wanwisa D;Liu C;Mongkolsapaya J;Bown A;Bailey D;Vipond R;Grayson N;Temperton N;Gupta S;Ploeg RJ;Bolton J;Fyfe A;Gopal R;Simmonds P;Screaton G;Thompson C;Brooks T;Zambon M;Miflin G;Roberts DJ
通讯作者：
Roberts DJ
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
19
作者：
Harvala, Heli;Mehew, Jennifer;Zambon, Maria
通讯作者：
Zambon, Maria
DOI：
10.1093/infdis/jiab283
发表时间：
2021-08-16
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Ratcliff J;Nguyen D;Fish M;Rynne J;Jennings A;Williams S;Al-Beidh F;Bonsall D;Evans A;Golubchik T;Gordon AC;Lamikanra A;Tsang P;Ciccone NA;Leuscher U;Slack W;Laing E;Mouncey PR;Ziyenge S;Oliveira M;Ploeg R;Rowan KM;Shankar-Hari M;Roberts DJ;Menon DK;Estcourt L;Simmonds P;Harvala H;REMAP-CAP Immunoglobulin Domain UK Investigators
通讯作者：
REMAP-CAP Immunoglobulin Domain UK Investigators